Treatment Access Solution

A collaboration with Cepheid

GeneXpert® & Xpert BCR ABL Assay

At the request of The Max Foundation, in 2012 Cepheid agreed to offer a preferential price for the GeneXpert®IV System and Xpert® BCR-ABL Monitor Assay for public sector end users in 68 countries. This preferential pricing was built into a shared-values collaboration agreement between The Max Foundation and Cepheid, and only applies to orders placed by The Max Foundation to Cepheid. End user institutions interested in taking advantage of the preferential pricing may inquire with The Max Foundation for guidance on how to access the program.

Download Max-Cepheid Agreement (PDF)

Visit our global map to see where this agreement is operating today. Contact us for more information about how your institution might benefit from our preferential pricing agreement.

Return to Treatment Access Solutions

Follow the Patient Journey

Join Gershon as he shares his journey from cancer patient to advocate and leader.
See Gershon's Journey
Gershon